FDA gets new teeth to police cell transplants; industry gets a say in rewriting rules
H.R. 1082 — Shandra Eisenga Human Cell and Tissue Product Safety Act · Filed by John Moolenaar (R-MI) · 1 cosponsor · Introduced Feb 6, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the FDA to run a public education campaign about cell and tissue transplants, establishes civil penalties (up to $20,000 per violation, capped at $10 million per proceeding) for companies that violate FDA regulations on human cell and tissue products, and directs the FDA to publish data on inspections, registrations, and regulatory timelines while holding public workshops and a docket to modernize how these products are regulated.
Why we flagged it
The bill's operative mechanism is twofold: (1) establishing civil penalties for FDA violations in cell/tissue product regulation, and (2) mandating public transparency and stakeholder engagement on regulatory modernization. Both are enforcement and accountability measures, not industry carve-outs.
What the text implies
- The $10 million cap on civil penalties per proceeding may limit deterrence if multiple violations occur in a single case, potentially allowing large manufacturers to treat penalties as a cost of doing business rather than a serious enforcement tool.
- The bill directs the FDA to hold public workshops and establish a docket on 'modernizing' cell/tissue product regulation, including review of 'minimal manipulation' and 'homologous use' standards—concepts that industry has long sought to relax. The outcome of this process is not predetermined, but the framing invites regulatory streamlining that could reduce safety oversight.
The full analysis lists 4 implications of this text.
Who stands to gain
cell and tissue product manufacturers; tissue establishments; biomedical consortia and research organizations